About this item:

150 Views | 85 Downloads

Author Notes:

Melissa M. Smarr, 1518 Clifton Road NE, Atlanta, GA, 30322, Office: (404) 727-3809. Fax: (404) 727-8744. melissa.smarr@emory.edu,

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Dr. Smarr conceptualized and performed the analysis, drafted the initial manuscript, and reviewed and revised the manuscript; Dr. Bible oversaw the statistical analysis, and critically reviewed the manuscript; Dr. Gerlanc and Ms. Bever assisted with the imputation analysis, and critically reviewed the manuscript; Drs. Buck Louis and Grantz conceptualized and designed the study, critically reviewed the manuscript.

We would like to acknowledge the research teams at all participating clinical centers, including Christina Care Health Systems; University of California, Irvine; Long Beach Memorial Medical Center; Northwestern University; Medical University of South Carolina; Columbia University; New York Hospital Queens; St. Peters’ University Hospital; University of Alabama at Birmingham; Women and Infants Hospital of Rhode Island; Fountain Valley Regional Hospital and Medical Center; and Tufts University.

Additionally, we acknowledge GE Healthcare Women’s Health Ultrasound for their support and training on the Voluson and ViewPoint products over the course of this study; along with C-TASC and the EMMES Corporation for providing data and imaging support for this multisite study.

The authors have no conflicts of interest relevant to this article to disclose.

Subjects:

Research Funding:

This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, contracts HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Pediatrics
  • THE-COUNTER MEDICATIONS
  • PARACETAMOL EXPOSURE
  • PREGNANCY
  • RISK
  • ANALGESICS
  • SINGLETONS
  • HEALTH

Comparison of fetal growth by maternal prenatal acetaminophen use

Tools:

Journal Title:

Pediatric Research

Volume:

Volume 86, Number 2

Publisher:

, Pages 261-268

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: Equivocal findings exist regarding prenatal acetaminophen use and various adverse neonatal and childhood health outcomes, though with no data on fetal growth. We evaluated whether fetal growth differed by maternal acetaminophen use. Methods: Racially diverse, healthy women with low-risk antenatal profiles from 12 US clinical centers were enrolled in a prospective cohort study and followed until delivery. Ultrasound measurements of fetal parameters and self-reported prenatal acetaminophen use were collected at enrollment and up to five follow-up visits. Prenatal acetaminophen use was dichotomized as none or any. Results: Among 2291 women, 932 (41%) reported the use of acetaminophen medications during the current pregnancy. Estimated growth curves of fetal parameters did not differ between women reporting use of any medication containing acetaminophen and women with no reported use of the same. Conclusion: Among healthy mothers with low-risk pregnancies, maternal acetaminophen use was not associated with alterations in fetal growth.

Copyright information:

© 2019, International Pediatric Research Foundation, Inc.

Export to EndNote